APIs pour la recherche et les impuretés

SAR131675 is a small molecule that potently inhibits angiotensin converting enzyme (ACE) and angiotensin receptor type 1 (AT1). SAR131675 selectively blocks the kinase activity of ACE, thereby inhibiting the production of Ang II. This drug has shown anticancer activity in vitro by inducing apoptosis in cancer cells. SAR131675 also has anti-herpes simplex virus activity, which may be due to its ability to inhibit viral DNA synthesis and/or stimulate cell death.

Ciprofibrate-o-β-glucuronide is the major metabolite of ciprofibrate in humans. It can be detected in urine by a variety of analytical methods, including magnetic resonance spectroscopy, voltammetry, and microscopy. Ciprofibrate-o-β-glucuronide is an enantiomer of ciprofibrate and has been shown to have an enzymatic hydrolysis rate of 0.07% per hour. This hydrolysis process is catalyzed by cytochrome P450 enzymes. Ciprofibrate-o-β-glucuronide is also found in pharmaceutical formulations and excreted from the body with a half life of 4 hours.

Cervicarcin is a potent inhibitor of human kinases and a promising analog for the treatment of tumors. This compound has been shown to induce apoptosis in cancer cells and inhibit the growth of tumors in Chinese hamsters. Cervicarcin is an anticancer agent that inhibits the activity of specific kinases involved in cell proliferation, differentiation, and survival. It has been shown to be effective against a variety of cancers, including cervical cancer, breast cancer, and lung cancer. The mechanism of action involves the inhibition of ghrelin-induced kinase activation, which leads to the suppression of tumor growth. Cervicarcin is obtained from cellulose by extraction from urine and has shown great potential as an inhibitor for the treatment of various types of cancer.

Atorvastatin is a drug product that is designed for the treatment of dyslipidemia, hypercholesterolemia, and mixed dyslipidemia. It is an impurity in the drug product Atorvastatin EP. Impurity B is a natural metabolite that has been found to have a niche market as an analytical standard for HPLC. The metabolite can be synthesized with high purity and quality standards, which are suitable for use in pharmacopoeia and research and development.

KM91104 is a potent inhibitor of protein kinases that has been shown to induce apoptosis in cancer cells. It is derived from a traditional Chinese medicinal plant and has demonstrated anticancer activity against various human cancer cell lines. KM91104 specifically targets the cell cycle and inhibits tumor growth by blocking the activity of certain proteins involved in cell division. This compound has also been found in urine samples, indicating that it may have potential as a diagnostic marker for cancer. Overall, KM91104 shows promising potential as an effective and selective inhibitor for the treatment of cancer.

N-(Diphenoxymethylene)-methanesulfonamide is a potent cancer kinase inhibitor that has been shown to induce apoptosis in human cancer cells. It is an analog of the anticancer drug staurosporine and inhibits a wide range of kinases, including cyclin-dependent kinases (CDKs) and protein kinase C. N-(Diphenoxymethylene)-methanesulfonamide has demonstrated significant activity against various tumor types in Chinese hamster ovary cells and has been shown to be effective in inhibiting the growth of several different cancer cell lines. This inhibitor can also be found in urine samples, indicating its potential use as a biomarker for cancer diagnosis and treatment monitoring. Overall, N-(Diphenoxymethylene)-methanesulfonamide represents a promising new class of anticancer agents with broad-spectrum kinase inhibition activity.

Enantiomer of Lamivudine